Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Aminoglutethimide 125 mg twice daily and hydrocortisone 20 mg twice daily was used to treat 76 postmenopausal women with advanced breast cancer. There were 4 CR, 17 PR (objective response rate 28%). Highest response was in soft tissue. CNS toxicity was less than with conventional dose AG (drowsiness 7% v. 31%), although the incidence of rash was equivalent. Previous responders to tamoxifen had a higher response (33%) than previous non-responders (9%). The lower toxicity and maintained efficacy suggest that this should be the standard dosage regimen.


Journal article


Breast Cancer Res Treat

Publication Date



7 Suppl


S41 - S44


Aged, Aminoglutethimide, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Dose-Response Relationship, Drug, Drug Evaluation, Female, Humans, Hydrocortisone, Liver Neoplasms, Lung Neoplasms, Menopause, Prognosis